
SAB Biotherapeutics (SABS) Stock Forecast & Price Target
SAB Biotherapeutics (SABS) Analyst Ratings
Bulls say
SAB Biotherapeutics is well positioned because FDA accelerated approval of Tzield in Stage 3 T1D validates C-peptide as an approvable surrogate endpoint, directly de-risking SAB-142’s ongoing SAFEGUARD trial, whose primary endpoint is stimulated C-peptide at 12 months. The company also appears differentiated on safety and dosing convenience: SAB-142 has shown low immunogenicity, no serum sickness, no neutropenia, and a repeat-dose profile that could support chronic use, while Tzield carries boxed-warning immune-related risks and a burdensome 14-day IV regimen. Fundamentally, the addressable opportunity remains large, with about 1.5 million people living with T1D in the U.S. and roughly 64,000 new cases per year, supporting meaningful upside if SAB-142 can capture even a modest share.
Bears say
SAB Biotherapeutics is a clinical-stage biotech with a history of losses, and the company expects significant operating deficits to continue as it funds research, preclinical work, and clinical development, making profitability uncertain. Its investment case is highly concentrated in SAB-142, while limited human clinical data, regulatory uncertainty with the FDA and EMA, and the risk of not meeting safety or efficacy endpoints create a binary outcome profile that could materially impair value. Financial risk is compounded by the need for future debt or equity financing, possible dilution, a herd-dependent manufacturing model with about 200 genetically engineered production animals in South Dakota, and intense competition from better-resourced rivals and existing products.
This aggregate rating is based on analysts' research of SAB Biotherapeutics and is not a guaranteed prediction by Public.com or investment advice.
SAB Biotherapeutics (SABS) Analyst Forecast & Price Prediction
Start investing in SAB Biotherapeutics (SABS)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About SAB Biotherapeutics (SABS) Forecast
SAB Biotherapeutics (SABS) Analyst Forecast & Price Prediction
Start investing in SAB Biotherapeutics (SABS)
Order type
Buy in
Order amount
Est. shares
0 shares